Christoph Ulrich Correll MD
Child & Adolescent Psychiatry
Medical Director, Recognition and Prevention (RAP) Program, Department of Psychiatry, The Zucker Hillside Hospital Investigator, Center for Psychiatric Neuroscience, The Feinstein Institute for Medical Research Professor, Psychiatry and Molecular Medicine, Hofstra Northwell School of Medicine
Join to View Full Profile
The Zucker Hillside Hospital Dept of Psych75 59 263RD StreetGlen Oaks, NY 11004
Phone+1 718-470-4812
Dr. Correll is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Zucker School of Medicine at Hofstra/Northwell at Zucker Hillside HospitalFellowship, Child and Adolescent Psychiatry, 2001 - 2003
Free Univ Berlin- Fac MedClass of 1993
Long Island Jewish Medical CenterResidency, Psychiatry
Certifications & Licensure
NY State Medical License 2013 - 2026
American Board of Psychiatry and Neurology Psychiatry- American Board of Psychiatry and Neurology Child & Adolescent Psychiatry
Clinical Trials
- Treating Drug-Resistant Childhood Schizophrenia Start of enrollment: 2001 Oct 01
- Antidepressant and Antipsychotic to Treat Attenuated Positive and Negative Symptoms Start of enrollment: 2004 Mar 01
- Clinical Risk State for Bipolar Disorder in Adolescents Start of enrollment: 2009 Sep 01
Publications & Presentations
PubMed
- 1 citationsLetter to the Editor Concerning "Glucagon-Like Peptide Agonists for Weight Management in Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis".Anders Fink-Jensen, Christoph U Correll
Acta Psychiatrica Scandinavica. 2025-04-01 - Association of Relapse With All-Cause Mortality in Adult Patients With Stable Schizophrenia.Christoph U Correll, Brahim K Bookhart, Carmela Benson, Zhiwen Liu, Zhongyun Zhao
The International Journal of Neuropsychopharmacology. 2025-04-01 - Continuous Dopamine DReceptor Blockade and Long-Term Outcome in First-Episode Schizophrenia.Jari Tiihonen, Antti Tanskanen, Marco Solmi, Jose M Rubio, Christoph U Correll
The American Journal of Psychiatry. 2025-04-01
Journal Articles
- Association Between Cardiovascular Risk Factors and Cognitive Impairment in People with SchizophreniaChristoph Correll, MD, JAMA Psychiatry
- Effectiveness of Transdiagnostic Cognitive-Behavioral Psychotherapy Compared with Management as Usual for Youth with Common Mental Health ProblemsChristoph Correll, MD, JAMA Psychiatry
- Impact of Comprehensive Treatment for First Episode Psychosis on Substance Use Outcomes: A Randomized Controlled TrialCorinne Cather, Robert Rosenheck, Christoph U Correll, Psychiatry Research
Authored Content
- Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
- Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
- Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
- Management of Patients with Severe Mental Illness During the Coronavirus Disease 2019 PandemicJune 2020
- Join now to see all
Press Mentions
Luye Pharma Announces U.S. Launch of ERZOFRI® (Paliperidone Palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective DisorderApril 7th, 2025- Spinogenix Announces Open Enrollment for Phase 2 US Trial Following FDA Clearance of IND Application for SPG302, the First Synaptic Regenerative Therapy for SchizophreniaMarch 30th, 2025
- A Lines of Therapy Analysis Found That Use of UZEDY as a First-Line Treatment Option Was at 12%. However, Patients Prescribed UZEDY Had Most Commonly Received Oral Second-Generation Antipsychotics as Their Initial TherapyNovember 1st, 2024
- Join now to see all
Grant Support
- Project 4 AcisrNational Institute Of Mental Health2010–2012
- Project 1 AcisrNational Institute Of Mental Health2010–2012
- Adverse Events Unit (Research Methods Core)National Institute Of Mental Health2010–2012
- 3/3-Improving Metabolic Parameters Of Antipsychotic Child Treatment (IMPACT)National Institute Of Mental Health2008–2011
- Improving Metabolic Parameters Of Antipsychotic Child Treatment (IMPACT)National Center For Research Resources2010
- Factors For Metabolic Abnormalities In Children With Psychiatric DisordersNational Center For Research Resources2010
- Biological And Genetic Risk Factors For Weight GAIN And Metabolic AbnormalitiesNational Center For Research Resources2007–2008
- Biological &Genetic Risk Factors For Anti-Psychotic Induced Weight GAIN &MeNational Center For Research Resources2005–2006
- Treating Refractory Childhood SchizophreniaNational Institute Of Mental Health2005
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
